Approved for Treatment of mild-to-moderate COVID-19 in adults and pediatric patients aged 12 years and older who are at high risk for progression to severe disease. Nirmatrelvir is a SARS-CoV-2 main protease (Mpro) inhibitor that blocks viral polyprotein processing. Ritonavir inhibits CYP3A-mediated metabolism of nirmatrelvir, boosting its plasma concentrations. Side effects, costs,…
Loading full data from Know Your Drugs Institute…